Scarica l'app Stockscreener
26.03
1.06%
-0.28
Dopo l'orario di chiusura:
26.50
0.47
+1.81%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IMVT Giù?
Forum
Previsione
Precedente Chiudi:
$26.31
Aprire:
$26.67
Volume 24 ore:
1.58M
Relative Volume:
0.88
Capitalizzazione di mercato:
$5.24B
Reddito:
-
Utile/perdita netta:
$-382.71M
Rapporto P/E:
-9.9351
EPS:
-2.62
Flusso di cassa netto:
$-325.64M
1 W Prestazione:
+0.46%
1M Prestazione:
+14.37%
6M Prestazione:
+50.55%
1 anno Prestazione:
+10.16%
Intervallo 1D:
$26.00
$27.80
Intervallo di 1 settimana:
$24.70
$27.80
Portata 52W:
$12.72
$27.80
Immunovant Inc Stock (IMVT) Company Profile
Nome
Immunovant Inc
Settore
Industria
Telefono
917-580-3099
Indirizzo
320 WEST 37TH STREET, NEW YORK, NY
Confronta IMVT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
26.03 | 5.30B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-06 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | Iniziato | Truist | Hold |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-03-03 | Iniziato | Jefferies | Hold |
| 2025-01-03 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-09 | Reiterato | Oppenheimer | Outperform |
| 2024-03-28 | Iniziato | Oppenheimer | Outperform |
| 2024-03-13 | Iniziato | Goldman | Buy |
| 2024-02-20 | Iniziato | JP Morgan | Overweight |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-13 | Aggiornamento | UBS | Neutral → Buy |
| 2023-09-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Iniziato | BofA Securities | Buy |
| 2023-04-25 | Iniziato | Citigroup | Buy |
| 2023-03-31 | Iniziato | Piper Sandler | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2023-02-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Downgrade | UBS | Buy → Neutral |
| 2021-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2021-08-03 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-01 | Downgrade | Stifel | Buy → Hold |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-10-12 | Iniziato | Guggenheim | Buy |
| 2020-10-08 | Iniziato | Stifel | Buy |
| 2020-10-02 | Iniziato | Credit Suisse | Outperform |
| 2020-08-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-07-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-24 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Immunovant Inc Borsa (IMVT) Ultime notizie
Immunovant CTO Stout sells $32k in IMVT stock - Investing.com
Immunovant stock hits 52-week high at $27.71 By Investing.com - Investing.com India
Market Recap: Can Immunovant Inc. stock maintain operating marginsWeekly Investment Summary & Real-Time Market Sentiment Alerts - ulpravda.ru
How Immunovant Inc. stock compares to industry benchmarksJuly 2025 Gainers & Smart Swing Trading Alerts - ulpravda.ru
How Immunovant Inc. stock performs in stagflationPortfolio Risk Report & Precise Trade Entry Recommendations - ulpravda.ru
What technical charts say about Immunovant Inc. stockWeekly Risk Summary & Free Fast Gain Swing Trade Alerts - ulpravda.ru
Wolfe Research upgrades Immunovant stock to Outperform on Graves’ disease potential By Investing.com - Investing.com South Africa
Wolfe Research Upgrades Immunovant (IMVT) - Nasdaq
Wolfe Research upgrades Immunovant stock to Outperform on Graves’ disease potential - Investing.com Nigeria
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT) - PR Newswire
Immunovant CEO Peter Salzmann sells $208,899 in stock - MSN
Wolfe Research Downgrades Immunovant (IMVT) - MSN
(IMVT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Immunovant (NASDAQ:IMVT) Nasdaq Today Immunology Innovation - Kalkine Media
Immunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
How Investors Are Reacting To Immunovant (IMVT) $550 Million Follow-On Equity Raise And Dilution - Sahm
Assenagon Asset Management S.A. Invests $3.31 Million in Immunovant, Inc. $IMVT - MarketBeat
Research Analysts Issue Forecasts for Immunovant Q3 Earnings - MarketBeat
Momentum Shift: How Immunovant Inc. stock responds to policy changesChart Signals & Consistent Income Trade Recommendations - Улправда
How Immunovant Inc. stock compares to growth peers2025 Top Gainers & Technical Confirmation Alerts - Улправда
Squarepoint Ops LLC Has $1.36 Million Stock Position in Immunovant, Inc. $IMVT - MarketBeat
How Immunovant Inc. stock responds to policy changesInflation Watch & Long-Term Safe Return Strategies - ulpravda.ru
Tuyl Christopher Van Sells 10,813 Shares of Immunovant (NASDAQ:IMVT) Stock - MarketBeat
Officer Van Tuyl Acquires 16,676 Of Immunovant Inc [IMVT] - TradingView — Track All Markets
Immunovant Executive Sells Shares to Cover Tax Obligations - TradingView — Track All Markets
First Week of IMVT February 2026 Options Trading - Nasdaq
Can Immunovant Inc. stock weather global recessionPortfolio Growth Summary & Low Drawdown Investment Strategies - DonanımHaber
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - AOL.com
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - The Motley Fool
Share Offerings Prompt Huge Insider Buying in These 3 Biotechs - AOL.com
Immunovant (IMVT) Is Up 14.0% After Roivant-Backed $550 Million Equity Raise For IMVT-1402Has The Bull Case Changed? - Yahoo Finance
The Goldman Sachs Group Forecasts Strong Price Appreciation for Immunovant (NASDAQ:IMVT) Stock - MarketBeat
Immunovant (IMVT) Is Up 14.0% After $550 Million Follow-On Backed By Roivant SciencesWhat's Changed - Sahm
Immunovant (IMVT) Stock News and Forecast for Dec. 14, 2025: $550M Financing Closes, Roivant Buys $350M, Analysts Update Targets - ts2.tech
Immunovant (IMVT) down 0.6% since last earnings report: Can it rebound? - MSN
EPS Watch: Why OrthoPediatrics Corp. stock appeals to dividend seekersWeekly Stock Report & Low Drawdown Trading Strategies - moha.gov.vn
Immunovant Raises $550 Million Through Stock Offering - The Globe and Mail
Insider Buying: Sciences Roivant Acquires 16,666,666 Shares of I - GuruFocus
Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings - MSN
Roivant Sciences buys Immunovant (IMVT) shares worth $349.9m By Investing.com - Investing.com Canada
Roivant Sciences buys Immunovant (IMVT) shares worth $349.9m - Investing.com
Roivant Sciences Ltd. Purchases 16.7 Million Immunovant Shares - TradingView — Track All Markets
Owner Roivant Sciences Ltd Buys 16,666,666 ($350M) Of Immunovant Inc [IMVT] - TradingView — Track All Markets
Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement - Seeking Alpha
Immunovant Enters Underwriting Agreement for Stock Offering - TradingView — Track All Markets
Immunovant (NASDAQ:IMVT) Stock Price Up 8.1%Here's Why - MarketBeat
Immunovant, Inc. $IMVT is Armistice Capital LLC's 9th Largest Position - MarketBeat
Immunovant announces $550 million stock offering - MSN
Latham & Watkins Advises on Immunovant’s US$550 Million Offering of Common Stock - Latham & Watkins LLP
Immunovant announces $550 million stock offering and clinical program updates - Investing.com Canada
Roivant Signals Major Pipeline Momentum With Accelerated Timelines - Sahm
Immunovant Inc Azioni (IMVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immunovant Inc Azioni (IMVT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Van Tuyl Christopher | Chief Legal Officer |
Dec 18 '25 |
Sale |
26.91 |
10,813 |
290,943 |
149,930 |
| Roivant Sciences Ltd. | Director |
Dec 12 '25 |
Buy |
21.00 |
16,666,666 |
349,999,986 |
113,317,007 |
| Fromkin Andrew J. | Director |
Dec 01 '25 |
Sale |
23.25 |
22,249 |
517,189 |
85,852 |
| Hughes Douglas J. | Director |
Dec 01 '25 |
Sale |
23.24 |
15,000 |
348,665 |
120,773 |
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):